37
Participants
Start Date
February 24, 2022
Primary Completion Date
February 28, 2025
Study Completion Date
December 30, 2025
avapritinib
oral administration
Medizinische Universitat Wein, Vienna
Sydney Children's Hospital, Kids Cancer Center, Sydney
Royal Children's Hospital, Parkville
Columbia University Medical Center, New York
UPMC Children's Hospital of Pittsburgh, Pittsburgh
Dipartimento di Oncologia Medica ed Ematologia - S.C. Pediatria Oncologica, Milan
The Johns Hopkins Hospital, Baltimore
Duke University Medical Center, Durham
Universitaetsmedizin Göttingen, Göttingen
Nationwide Children's Hospital, Columbus
University of Michigan, Ann Arbor
Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago
Washington University School of Medicine, St Louis
Children's Medical Center, Dallas
University of Texas MD Anderson Cancer Center, Houston
Children's Hospital Colorado, Aurora
Phoenix Children's Hospital, Phoenix
University of California San Francisco, Benioff Children's Hospital, San Francisco
Gustave Roussy, Villejuif
Oregon Health and Science University, Portland
Dana Farber Cancer Institute, Boston
The Hospital for Sick Children, Toronto
Hopp Children's Cancer Center, Heidelberg
Asan Medical Center, Seoul
Samsung Medial Center, Seoul
Great Ormond Street Hospital For Children, London
Lead Sponsor
Blueprint Medicines Corporation
INDUSTRY